Birdshot Retinochoroidopathy

Birdshot retinochoroidopathy is a rare, long-lasting inflammation that affects the back of both eyes. The problem lives in two layers: the retina (the light-sensing tissue) and the choroid (the blood-rich layer under the retina). Doctors see many pale, oval or round spots in the back of the eye that look like a birdshot pattern—hence the name. The disease usually shows up in adults in mid-life and tends to be slowly progressive without treatment. It is strongly linked to a genetic marker called HLA-A29. Most patients who truly have this disease carry HLA-A29, and modern genetic testing (PCR) detects it more accurately than older blood tests. American Academy of Ophthalmology+2NCBI+2

Birdshot retinochoroidopathy is a bilateral (both eyes), chronic (long-lasting) inflammation in the back of the eyes. It causes creamy, oval spots deep in the eye wall, vitreous haze (tiny cells in the eye’s gel), retinal vessel leakage, and sometimes macular swelling. Over time it can reduce vision, night vision, and contrast sensitivity if not controlled. The disease has no known infection that causes it. Instead, the immune system—shaped by genes such as HLA-A29 and enzymes like ERAP2—appears to mis-recognize some retinal or choroidal targets and drives inflammation. American Academy of Ophthalmology+2PubMed+2

Birdshot retinochoroidopathy (also called birdshot chorioretinopathy or HLA-A29 uveitis) is a rare, long-lasting inflammation in the back of the eye. It attacks the choroid and retina. Doctors believe it is an autoimmune disease. Most patients carry the genetic marker HLA-A29. Typical symptoms include blurry vision, floaters, poor night vision, glare, and color changes. The disease can slowly damage the retina and cause vision loss if not treated. Modern imaging (OCT, fluorescein and indocyanine angiography, autofluorescence) helps diagnosis and follow-up. Treatment aims to control inflammation, protect the macula, and preserve visual field over years. PMC+2EyeWiki+2

Other names

You may also hear these names used for the same condition:

• Birdshot chorioretinopathy

• Birdshot retinochoroiditis

• Birdshot uveitis

• HLA-A29 uveitis

• Vitiliginous chorioretinitis

All of these terms describe the same clinical entity: a bilateral posterior uveitis with cream-colored, birdshot-like choroidal spots and a very strong association with HLA-A29. Some experts prefer “HLA-A29 uveitis” because the HLA link is so strong. PMC+1

Types

There is no single official list of “types,” but clinicians often group cases in practical ways:

1. Activity over time: active vs. inactive (“burned-out”)
   In the active phase, patients have new or worsening floaters, blurred vision, and imaging shows leakage or active lesions. In inactive or burned-out disease, the spots may remain but the inflammation is quiet; ERG and visual field can still show damage from the past. NCBI

2. Phenotype by dominant tissue involvement
   Some patients show more choroidal lesions (the classic birdshot spots), while others have more retinal vasculitis and macular issues on fluorescein angiography and OCT. The clinical picture and imaging guide therapy intensity. American Academy of Ophthalmology

3. Imaging-based patterns/stages
   A helpful pattern is that indocyanine-green angiography (ICG) may reveal many small hypofluorescent dark dots that reflect choroidal involvement—even when the classic spots are subtle or not yet visible. This can be considered an “ICG-positive” pattern that helps confirm the diagnosis and track disease. PubMed+1

Causes

The exact cause is unknown. What follows are factors that research suggests contribute to risk or help explain why the disease happens. I list them in plain language and keep them evidence-minded.

1. HLA-A29 positivity — the strongest known risk; almost all definite cases carry it. PMC

2. HLA-A29 subtypes (e.g., A29:02) — specific subtypes show very high odds ratios for disease. PMC

3. ERAP2 genetic variants — genes that trim peptides for HLA presentation (ERAP2, sometimes ERAP1) shape the immune repertoire involved in birdshot. PubMed

4. Class I HLA-peptide presentation pathway — altered antigen presentation may trigger retinal/choroidal auto-reactivity. PMC

5. T-cell–driven immunity — adaptive immune responses likely target eye antigens presented by HLA-A29. PMC

6. Middle age — typical age of onset is mid-life (often 40s–60s). PubMed

7. European ancestry — reported more commonly in people of Western/Northern European descent, likely reflecting HLA-A29 distribution. PubMed

8. Immune dysregulation without systemic organ disease — inflammation is eye-limited; systemic triggers are usually not found. PubMed

9. Genetic–environment interaction — genetics are necessary but may not be sufficient; environment likely modulates risk. (Inference consistent with HLA-linked diseases.) PMC

10. Possible molecular mimicry — theory that non-self peptides mimic ocular peptides, priming T cells; evidence remains indirect. PMC

11. Retinal/choroidal autoantigens — candidate targets are suspected but not definitively proven in routine care. PMC

12. Choroidal small-vessel involvement — ICG points to patchy choroidal hypoperfusion/dots, suggesting vascular/chorio-retinal interface is central. Nature

13. Breakdown of the blood-retina barrier — seen as leakage on fluorescein; facilitates immune cell access. American Academy of Ophthalmology

14. Chronicity — once triggered, ongoing immune memory likely sustains disease. (General immunology principle applied to BSCR.) PMC

15. Female sex (slight predominance noted in some series) — modest signal, not deterministic. ResearchGate

16. Lack of infectious cause — infections are usually ruled out; BSCR is not driven by a proven microbe. American Academy of Ophthalmology

17. No extra-ocular disease driver — unlike sarcoid or Behçet, birdshot is typically eye-limited. PubMed

18. HLA-A29 population frequency — where A29 is common, birdshot is reported more often (epidemiologic correlation). PMC

19. Immune amplification loops — persistent retinal inflammation can self-perpetuate once initiated. (Mechanistic framework supported by chronic uveitis literature.) PMC

20. Other genes near ERAP locus (5q15) — combined ERAP1/ERAP2 haplotypes modify risk in A29-positive people. Wikipedia

Symptoms

1. Blurred vision — inflammation and leakage in the macula make central vision less sharp. American Academy of Ophthalmology

2. Floaters — tiny cells and debris in the vitreous cast shadows that patients see as moving specks. American Academy of Ophthalmology

3. Poor night vision (nyctalopia) — damage to retinal cells and choroidal supply reduces low-light seeing. NCBI

4. Light sensitivity (photophobia) — active inflammation makes bright light uncomfortable. NCBI

5. Reduced contrast sensitivity — fine differences between light and dark are harder to detect; daily tasks feel “washed out.” NCBI

6. Color vision changes — colors may look dull or “off” because retinal function is impaired. NCBI

7. Visual field defects — patchy blind spots arise from retinal/choroidal lesions; patients may bump into things. ScienceDirect

8. Wavy or distorted lines (metamorphopsia) — macular swelling or scars bend straight lines. American Academy of Ophthalmology

9. Glare and halos — scattering from vitreous cells and macular changes causes light artifacts. NCBI

10. Trouble adapting from light to dark — damaged photoreceptors adapt more slowly. NCBI

11. Paracentral spots in vision — scotomas near the center reflect localized retinal dysfunction. ScienceDirect

12. Headache or eye ache — less common, but eye strain and inflammation can feel uncomfortable. NCBI

13. Reduced reading speed — blurred central vision and low contrast slow reading. NCBI

14. Difficulty with driving at night — due to combined night vision and glare problems. NCBI

15. Overall visual fatigue — sustained effort to see clearly leads to tired eyes. NCBI

Diagnostic tests

A) Physical exam (in-clinic observation and basic measures)

1. Comprehensive eye exam with dilated funduscopy — the doctor looks for the signature cream-colored choroidal spots in both eyes, checks for vitreous cells, and assesses blood vessels and macula. The classic pattern plus bilateral involvement strongly suggests birdshot. American Academy of Ophthalmology

2. Best-corrected visual acuity (VA) — measures sharpness with glasses in place. In birdshot, VA can be normal early but often worsens as the macula is involved. NCBI

3. Pupil exam and intraocular pressure (IOP) — rules out other causes and looks for secondary effects; birdshot usually has normal IOP and lacks heavy anterior inflammation. EyeWiki

4. Slit-lamp exam — checks the front of the eye for mild anterior chamber cells (often none or mild), and the vitreous for inflammatory cells (vitritis). These help grade activity. EyeWiki

5. Color fundus photography — documents the number, size, and distribution of spots over time to monitor change. American Academy of Ophthalmology

B) Manual/functional chairside tests

6. Amsler grid testing — a simple square grid used by patients to detect wavy lines or missing areas that indicate macular dysfunction. NCBI

7. Automated or manual visual field testing (perimetry) — maps blind spots and peripheral vision loss; correlates with ERG and disease burden. ScienceDirect

8. Contrast sensitivity cards (e.g., Pelli-Robson) — quantify the “washed-out” vision patients describe; sensitive to macular and post-receptoral dysfunction. NCBI

9. Color vision plates (Ishihara or similar) — identify acquired color defects caused by retinal inflammation. NCBI

10. Dark adaptation assessment — formal or informal tests gauge how quickly vision recovers in low light, which is often impaired. NCBI

C) Lab and pathological tests (mostly to confirm HLA and to exclude mimics)

11. HLA-A29 typing (ideally PCR-based genotyping) — a strong supportive test; modern PCR reduces false negatives compared with older serology. A positive test powerfully supports the diagnosis in the right clinical picture. PMC

12. Basic inflammatory markers (ESR, CRP) — can be normal or mildly raised; mostly used to check for other systemic inflammatory diseases. NCBI

13. Infectious rule-out panel (syphilis, TB) as indicated — birdshot is not an infection, but look-alikes must be excluded according to local protocols. NCBI

14. Sarcoid screening (ACE/lysozyme or imaging if suspected) — to rule out sarcoidosis, which can mimic posterior uveitis. NCBI

15. Autoimmune screens (as guided by history) — targeted testing when other uveitic entities are in the differential; these are not diagnostic for birdshot itself. NCBI

D) Electrodiagnostic tests (measure retinal function directly)

16. Full-field ERG (including 30-Hz flicker) — one of the most informative tests. In birdshot, the 30-Hz flicker implicit time is often delayed, and amplitude may be reduced. ERG tracks disease over time and can worsen before vision drops, so it helps guide therapy. PMC

17. Pattern ERG or multifocal ERG (mfERG) — these can highlight macular dysfunction and complement full-field ERG in monitoring. PMC

E) Imaging tests (visualizing leakage, lesions, and structure)

18. Fluorescein angiography (FA) — shows retinal vascular leakage, optic disc leakage, and macular edema if present. It maps active retinal inflammation. American Academy of Ophthalmology

19. Indocyanine-green angiography (ICG) — the most characteristic choroidal test. It shows multiple small hypofluorescent dark dots across the fundus in almost all patients during active disease; these represent choroidal involvement and can persist. ICG is invaluable for diagnosis and follow-up. PubMed+1

20. Optical coherence tomography (OCT) and OCT-angiography (OCT-A) — OCT reveals macular edema, photoreceptor damage, and retinal thinning; OCT-A can show flow deficits. OCT changes often correlate with ERG and clinical status. PubMed

Non-pharmacological treatments (therapies & other measures)

Important: These measures support medical therapy; they do not replace anti-inflammatory medicines your doctor prescribes.

1. Regular specialist follow-up and imaging
   Seeing a uveitis/retina specialist on a schedule is the foundation of care. Exams track inflammation in the vitreous, retina, and choroid. OCT checks macular edema. Fluorescein and indocyanine angiography map leakage and choroidal lesions. Autofluorescence and visual field testing follow damage patterns over time. Early treatment changes prevent permanent retinal injury. This steady monitoring reduces vision loss in chronic posterior uveitis, which includes birdshot. PMC+1

2. Sun protection and glare control
   Bright light can worsen glare and photophobia. Wraparound sunglasses and hats lower retinal light exposure and make daily tasks easier. Photochromic or polarized lenses can improve comfort outdoors and when driving. These simple tools improve quality of life while the medical team controls inflammation. EyeWiki

3. Low-vision rehabilitation
   If vision fluctuates, early referral for low-vision services helps. Magnifiers, contrast enhancement, task lighting, and orientation strategies keep reading and work possible. Rehabilitation teaches ways to use remaining vision efficiently, reducing disability while treatment continues. National Eye Institute

4. Smoking cessation (and avoid vaping)
   Smoking increases risk and severity of uveitis and macular complications. Quitting lowers inflammatory triggers and may improve outcomes. Newer data also link e-cigarettes with higher uveitis risk. Counseling, nicotine replacement, and support programs are recommended. Review of Optometry+3AAO Journal+3PMC+3

5. Vaccination planning
   Because many patients need immune-modulating drugs, the team reviews vaccines (e.g., influenza) before starting therapy. Live vaccines are generally avoided while on strong immunosuppressants. Coordinating with primary care reduces infection risk without flares. AAO Journal

6. Systemic health optimization
   Control blood pressure, lipids, and glucose. General cardiovascular health supports retinal microvasculature and recovery from macular edema. Primary care co-management improves overall outcomes in chronic ocular inflammation. National Eye Institute

7. Dry eye and surface care
   Lubricant drops, lid hygiene, and screen-time breaks relieve surface irritation that often worsens light sensitivity and blur. Comfortable ocular surfaces help patients tolerate necessary steroid or mydriatic drops. nhs.uk

8. Stress management and sleep hygiene
   Chronic autoimmune diseases can flare with stress and poor sleep. Relaxation training, CBT-I, and regular sleep schedules reduce fatigue and may help symptom control alongside medications. PMC

9. Safe exercise
   Moderate activity supports mood, sleep, and cardiometabolic health and is generally safe in uveitis. It can also help patients tolerate long courses of steroids by limiting weight gain and bone loss (with medical guidance). National Eye Institute

10. Nutrition pattern with anti-inflammatory focus
    A Mediterranean-style diet rich in fruits, vegetables, whole grains, legumes, and fish supports general inflammatory balance. While no diet cures birdshot, healthy patterns support eye and systemic health during prolonged therapy. National Eye Institute

11. Blue-light and screen comfort strategies
    High-contrast settings, breaks, and room lighting reduce glare and eye strain. These practical changes improve tolerance of near work during recovery from macular edema. National Eye Institute

12. Occupational accommodations
    Task-specific lighting, larger monitors, and flexible schedules help patients continue work while vision fluctuates. Early workplace adjustments prevent unnecessary disability. National Eye Institute

13. Driving safety checks
    Night driving can be difficult due to nyctalopia and glare. Periodic visual field and acuity assessments guide safe driving decisions and licensing requirements. EyeWiki

14. Infection avoidance practices
    Hand hygiene and prompt evaluation of fevers are important when on immunosuppression. This reduces serious infection risks without interrupting eye treatment. AAO Journal

15. Bone and metabolic protection during steroids
    Discuss calcium/vitamin D intake, weight-bearing exercise, and bone density monitoring when taking systemic steroids. This lowers long-term harm from necessary anti-inflammatory therapy. National Eye Institute

16. IOP monitoring routine
    Steroids can raise intraocular pressure. Regular pressure checks allow early treatment to prevent glaucoma damage, especially after intravitreal implants. FDA Access Data

17. Cataract preparedness
    Steroids and chronic inflammation can cause cataracts. Planning timing, control of inflammation before surgery, and lens choices improves outcomes when surgery is needed. Mount Sinai Health System

18. Macular-edema self-awareness
    Patients learn early signs (worsening central blur, distortion) and seek quick care. Fast treatment changes limit permanent macular damage. National Eye Institute

19. Medication adherence skills
    Using reminder apps, clear written plans, and family support keeps dosing consistent for drops, injections, and systemic drugs—key for long-term control. National Eye Institute

20. Patient education & support networks
    Understanding this HLA-A29-linked disease and its long path helps patients stay engaged with care. Support groups and reliable educational sites reduce anxiety and improve adherence. PMC+1

---

Drug treatments

Notes: Birdshot uveitis often needs long-term, steroid-sparing therapy. Some drugs below are FDA-approved for noninfectious posterior/intermediate/panuveitis; others are used off-label based on uveitis evidence and guidelines. Always use these under specialist care.

1. Adalimumab (Humira; TNF-α inhibitor) — FDA-approved for noninfectious uveitis
   Dose/Time: Adult SC regimen typically 80 mg loading, then 40 mg every other week (pediatric dosing differs). Purpose/Mechanism: Blocks TNF-α to dampen ocular inflammation and macular edema. Use: Effective in noninfectious intermediate/posterior/panuveitis; widely used as steroid-sparing in birdshot. Side effects: Infection risk (TB, fungal), injection site reactions, rare demyelination, malignancy warnings. Evidence: VISUAL trials and label approval for uveitis; birdshot patients were included among trial participants. FDA Access Data+1

2. Dexamethasone 0.7 mg intravitreal implant (Ozurdex) — FDA-approved for posterior uveitis
   Dose/Time: In-office intravitreal implant; effect ~3–6 months; repeat as needed. Purpose/Mechanism: Local steroid reduces vitreous haze and macular edema. Use: Useful for unilateral flares or when systemic therapy is contraindicated. Side effects: IOP rise, cataract, rare endophthalmitis. Evidence/Label: Indicated for noninfectious uveitis affecting the posterior segment. FDA Access Data

3. Fluocinolone acetonide 0.18 mg intravitreal implant (YUTIQ) — FDA-approved
   Dose/Time: Office implant with ~36-month steroid release. Purpose/Mechanism: Long-term local steroid to suppress recurrences. Use: For chronic relapsing posterior uveitis when durable suppression is needed. Side effects: Cataract and IOP elevations are common; glaucoma meds or surgery may be needed. Evidence/Label: NDA approval for chronic noninfectious posterior uveitis. FDA Access Data+1

4. Fluocinolone acetonide 0.59 mg implant (Retisert) — FDA-approved
   Dose/Time: Surgical pars plana implantation; releases steroid ~30 months. Purpose: Long-term control of intraocular inflammation. Use: For severe bilateral disease when systemic therapy is unsuitable. Side effects: High rates of cataract extraction and glaucoma procedures. Evidence/Label: Approved for chronic noninfectious posterior uveitis. molinahealthcare.com

5. Prednisone (systemic corticosteroid) — cornerstone
   Dose/Time: Typical start 0.5–1 mg/kg/day, then slow taper; goal is lowest effective dose. Purpose/Mechanism: Broad anti-inflammatory and immunosuppressive effects to rapidly control flares. Use: Often first-line bridge while starting steroid-sparing therapy. Side effects: Weight gain, hyperglycemia, hypertension, osteoporosis, mood changes. Evidence: Standard of care for noninfectious uveitis; prolonged low-dose strategies reported in birdshot cohorts. Label describes systemic risks. MDPI+1

6. Triamcinolone acetonide (periocular/intravitreal injection)
   Dose/Time: Sub-Tenon’s or intravitreal suspension (office-based). Purpose: Local steroid to reduce macular edema and haze. Use: Useful for unilateral or asymmetric disease; avoids systemic side effects. Side effects: IOP rise, cataract. Evidence: Widely used in uveitis practice; injectable label details steroid risks. FDA Access Data

7. Methotrexate (antimetabolite; off-label for birdshot)
   Dose/Time: 10–25 mg weekly PO/SC with folic acid; adjust by response. Purpose/Mechanism: Inhibits folate-dependent pathways and T-cell activity to allow steroid taper. Side effects: Cytopenias, liver enzyme elevation, stomatitis; avoid in pregnancy. Evidence: Recommended in uveitis guidelines as a steroid-sparing agent; label provides safety profile. AAO Journal+1

8. Mycophenolate mofetil (CellCept; antimetabolite; off-label)
   Dose/Time: Commonly 1–1.5 g twice daily. Purpose: Inhibits lymphocyte purine synthesis to control ocular inflammation. Side effects: GI upset, leukopenia, infection risk; teratogenic. Evidence: Common steroid-sparing in birdshot cohorts; label documents immunosuppressive risks. bjo.bmj.com+1

9. Azathioprine (Imuran; antimetabolite; off-label)
   Dose/Time: ~1–2 mg/kg/day; check TPMT activity. Purpose: Purine analog that dampens lymphocyte proliferation. Side effects: Myelosuppression, hepatotoxicity, infection risk. Evidence: Historic uveitis agent; label provides core safety and monitoring guidance. FDA Access Data

10. Cyclosporine (calcineurin inhibitor; off-label)
    Dose/Time: Often 2–5 mg/kg/day divided; monitor levels, BP, renal function. Purpose/Mechanism: Inhibits T-cell activation via calcineurin blockade. Side effects: Nephrotoxicity, hypertension, tremor. Evidence: Effective steroid-sparing in birdshot series; label outlines boxed warnings. FDA Access Data

11. Tacrolimus (calcineurin inhibitor; off-label)
    Dose/Time: Low-dose systemic with level monitoring. Purpose: Similar to cyclosporine with different toxicity profile. Side effects: Nephrotoxicity, neurotoxicity, diabetes risk. Evidence: Used in refractory noninfectious uveitis; label informs safety. EyeWiki

12. Infliximab (Remicade; TNF-α inhibitor; off-label in uveitis)
    Dose/Time: IV 5–10 mg/kg at weeks 0,2,6 then q4–8 weeks. Purpose: Blocks TNF-α to control posterior uveitis and macular edema. Side effects: Serious infection risk, infusion reactions, TB reactivation. Evidence: Used for refractory noninfectious uveitis; label details risks and dosing framework. FDA Access Data

13. Upadacitinib (Rinvoq; JAK inhibitor; off-label)
    Dose/Time: Extended-release oral; uveitis use is investigational. Purpose: JAK pathway inhibition reduces inflammatory cytokine signaling. Risks: Boxed warnings for serious infections, MACE, thrombosis, malignancy. Evidence: Consider only in research/specialist settings; label outlines risks. FDA Access Data

14. Rituximab (anti-CD20; off-label)
    Dose/Time: IV cycles with premedication; individualized schedules. Purpose: Depletes B cells in selected refractory cases or overlap autoimmune disease. Risks: Infusion reactions, HBV reactivation, PML (boxed warnings). Evidence: Case-based use in stubborn uveitis; label guides safety. FDA Access Data

15. Topical cycloplegics (e.g., atropine/homatropine) for comfort and synechiae prevention
    Dose/Time: Short courses during anterior spillover. Purpose: Relieves ciliary spasm pain and prevents iris-lens adhesions. Risks: Light sensitivity, near blur. Evidence: Standard uveitis supportive therapy. EyeWiki

16. Topical corticosteroids for anterior spillover
    Dose/Time: Intensive prednisolone acetate 1% then taper per activity. Purpose: Rapid anterior chamber quieting to protect the cornea and lens. Risks: IOP rise, cataract with prolonged use. Evidence: Core element in uveitis care. EyeGuru

17. Periocular steroid depot (posterior sub-Tenon’s triamcinolone)
    Dose/Time: Clinic injection for posterior segment inflammation; effect weeks to months. Purpose: Bridges to systemic control or treats unilateral flares. Risks: IOP/cataract. Evidence: Established in posterior uveitis practice; steroid labeling informs safety. FDA Access Data

18. Systemic steroid-sparing combinations (e.g., methotrexate + adalimumab)
    Purpose: Achieve durable control with minimal daily prednisone; protect macula and fields. Evidence: Trials and practice patterns support biologic + antimetabolite in noninfectious posterior uveitis; birdshot cohorts show steroid-sparing success. PMC+1

19. Fluocinolone 0.19 mg implant (Iluvien) — DME-approved; off-label in uveitis
    Dose/Time: Injected implant lasting up to 36 months. Use: Selected refractory cases when other options fail and glaucoma risk is acceptable. Risks: Cataract and IOP elevation. Evidence/Label: FDA-approved for DME; off-label reports in uveitis. FDA Access Data+1

20. Abatacept (CTLA-4-Ig; off-label, specialist use)
    Purpose: Inhibits T-cell costimulation; considered in refractory birdshot in limited studies. Risks: Infection risk; infusion reactions. Evidence: Small series suggest benefit in active birdshot uveitis not controlled by other agents. bjo.bmj.com

---

Dietary molecular supplements

Evidence for supplements in birdshot is limited; these do not replace medical therapy.

1. Vitamin D
   Dose: Often 800–2000 IU/day, individualized by blood levels. Function/Mechanism: Supports immune regulation and bone health during steroids; low levels link to higher inflammatory disease activity in many conditions. Note: Test and dose with clinician guidance to avoid toxicity. PMC

2. Omega-3 fatty acids (EPA/DHA)
   Dose: ~1–2 g/day combined EPA+DHA. Function: Modulate membrane eicosanoids and resolve inflammation, possibly easing macular edema adjunctively. Mechanism: Compete with arachidonic acid to reduce pro-inflammatory mediators. PMC

3. Lutein + Zeaxanthin
   Dose: As in AREDS2 (10 mg lutein + 2 mg zeaxanthin/day). Function: Antioxidant support for macula; may aid contrast and glare. Mechanism: Filter blue light and quench reactive oxygen species in photoreceptors. Iluvien

4. Curcumin (with piperine for absorption)
   Dose: Commonly 500–1000 mg/day standardized curcumin (medical guidance). Function: Anti-inflammatory polyphenol; experimental models of uveitis show cytokine down-regulation. Mechanism: NF-κB pathway modulation. PMC

5. Resveratrol
   Dose: ~150–250 mg/day (consult physician). Function: Antioxidant with anti-inflammatory effects seen in ocular models. Mechanism: SIRT1/AMPK pathways may reduce oxidative stress. PMC

6. Vitamin A (retinoids) — caution
   Dose: Only if deficient; avoid excess. Function: Supports photoreceptor health. Mechanism: Visual cycle component; deficiency harms night vision. Note: High doses can be toxic; check with clinician. National Eye Institute

7. Vitamin C
   Dose: ~200–500 mg/day from diet/supplement. Function: General antioxidant support for ocular tissues under inflammatory stress. Mechanism: Scavenges free radicals. National Eye Institute

8. Vitamin E
   Dose: ~100–200 IU/day from diet/supplement. Function: Lipid-phase antioxidant; may support retinal cell membranes. Mechanism: Interrupts lipid peroxidation chains. National Eye Institute

9. Zinc
   Dose: ~8–11 mg/day (RDA; avoid excess). Function: Co-factor in antioxidant enzymes; supports immune function. Mechanism: Stabilizes cellular defense pathways. Caution: Too much zinc can harm copper balance. National Eye Institute

10. Coenzyme Q10
    Dose: ~100–200 mg/day. Function: Mitochondrial co-factor; general oxidative stress support. Mechanism: Electron transport and antioxidant roles in retinal cells. PMC

---

Immunity-booster / regenerative / stem-cell” drugs

Safety note: There are no FDA-approved “stem-cell drugs” for birdshot uveitis. Unregulated stem-cell injections in the eye can cause blindness. Consider only within regulated clinical trials. Below are legitimate immune-modulating drugs used by specialists to restore immune balance—not “boosters.” National Eye Institute

1. Adalimumab (immune-modulating biologic)
   About 100 words: TNF-α inhibitor that re-balances overactive cytokine pathways in noninfectious uveitis. Dosing is subcutaneous on a regular schedule. It reduces retinal inflammation and macular edema and allows steroid tapering. Risks include infections and rare serious adverse events; screening for TB and hepatitis is required. Use is guided by uveitis specialists and based on FDA-approved labeling for uveitis. FDA Access Data

2. Methotrexate (steroid-sparing immune regulator)
   Low-dose weekly methotrexate calms T-cell–driven inflammation and helps patients get off daily prednisone. Folate supplementation lowers side effects. Regular labs (blood counts and liver enzymes) are essential. MTX is widely used across noninfectious uveitis as a first steroid-sparing drug when biologics are not yet indicated. AAO Journal+1

3. Mycophenolate mofetil (immune regulator)
   This antimetabolite selectively inhibits lymphocyte proliferation. Twice-daily dosing is common. It is often combined with a biologic or used alone to maintain remission once eyes are quiet. Careful blood and infection monitoring is necessary. It is teratogenic; strict pregnancy prevention is required. FDA Access Data

4. Cyclosporine or tacrolimus (calcineurin inhibitors)
   These agents directly inhibit T-cell activation and cytokine release. They are considered when antimetabolites are not tolerated. Blood pressure, kidney function, and drug levels require monitoring to stay safe and effective. FDA Access Data

5. Dexamethasone/fluocinolone implants (local, long-acting steroids)
   These are not “stem cells,” but they locally suppress inflammation for months to years with minimal systemic exposure. They’re options when systemic therapy is risky or not effective enough. Patients must be monitored for pressure rise and cataract. FDA Access Data+1

6. Abatacept (select cases; research-supported use)
   Blocks T-cell costimulation in highly refractory birdshot uveitis. Given IV or SC under specialist supervision with infection monitoring. Consider only after standard options fail. bjo.bmj.com

---

Surgeries (procedures and why they are done)

1. Fluocinolone implant surgery (Retisert)
   Procedure: Small scleral incision and pars plana placement in the operating room. Why: Delivers continuous steroid for ~30 months when long-term intraocular suppression is needed. Note: High cataract/IOP risks; often leads to glaucoma medications or surgery. molinahealthcare.com

2. In-office steroid implants (Ozurdex, Yutiq)
   Procedure: Intravitreal injection through a micro-applicator. Why: Sustained steroid delivery to control posterior uveitis and macular edema without systemic exposure. Follow-up: IOP and lens monitoring. FDA Access Data+1

3. Cataract surgery
   Procedure: Phacoemulsification with IOL implantation once inflammation is well-controlled. Why: Restores clarity when cataract forms from disease or steroids. Plan: Peri-operative anti-inflammatory control is essential. Mount Sinai Health System

4. Glaucoma surgery (e.g., trabeculectomy or tube shunt)
   Procedure: Creates new drainage or places a tube to lower eye pressure. Why: Treats steroid-induced or uveitic glaucoma not controlled with drops. FDA Access Data

5. Pars plana vitrectomy
   Procedure: Removes vitreous gel and inflammatory debris; can peel membranes if needed. Why: Improves vision when floaters, membranes, or complications persist and helps with diagnosis in complex cases. Mount Sinai Health System

---

Preventions (practical ways to reduce risk of flares/complications)

1. Do not stop or taper medicines on your own; taper only with your doctor. National Eye Institute

2. Keep every follow-up and imaging appointment; chronic diseases change slowly. National Eye Institute

3. Quit smoking and avoid vaping; both are linked to uveitis risk and worse outcomes. AAO Journal+1

4. Get vaccine planning before starting strong immunosuppressants. AAO Journal

5. Manage blood pressure, glucose, and cholesterol. National Eye Institute

6. Protect eyes from bright light with sunglasses and hats. EyeWiki

7. Report new central blur or distortion fast—macular edema needs quick care. National Eye Institute

8. Monitor eye pressure regularly, especially after steroid implants. FDA Access Data

9. Maintain bone health habits during long steroid courses. National Eye Institute

10. Avoid unapproved stem-cell injections; seek only regulated trials. National Eye Institute

---

When to see doctors (now vs. routine)

• Seek urgent care now for sudden vision drop, a dark curtain, severe new floaters, eye pain, halos, or severe light sensitivity. These can mean macular edema, retinal tear, high pressure, or infection. National Eye Institute

• Call within 24–48 hours if you notice new distortion, color changes, or night-vision worsening; these suggest activity and macular involvement. EyeWiki

• Keep routine visits every few weeks to months (per your specialist) for exam, OCT, and lab monitoring while on systemic therapy. National Eye Institute

---

What to eat and what to avoid

• Eat: Plenty of colorful vegetables and fruits; whole grains; legumes; nuts; fish rich in omega-3 (e.g., sardines, salmon). These foods support general anti-inflammatory balance. National Eye Institute

• Eat: Sources of lutein/zeaxanthin (spinach, kale, corn, egg yolk) to support macular health. Iluvien

• Eat: Adequate calcium and vitamin D (diet plus safe sun or supplements) when using steroids long-term. National Eye Institute

• Avoid/limit: Smoking/vaping, ultra-processed foods, and excess added sugars which worsen systemic inflammation. AAO Journal

• Avoid: High-dose supplements without medical advice; some interact with immunosuppressants. FDA Access Data

• Avoid: Alcohol excess, which can interact with methotrexate and raise liver risks. FDA Access Data

• Be careful: Grapefruit with cyclosporine/tacrolimus—it can alter drug levels. FDA Access Data

• Balance: Lean proteins and fiber to help weight and glucose control during steroids. National Eye Institute

• Hydrate: Regular water intake supports general health on systemic medications. National Eye Institute

• Personalize: Ask your doctor/dietitian to tailor intake to labs, bone health, and comorbidities. National Eye Institute

---

FAQs

1. Is birdshot caused by infection?
   No. It is an autoimmune inflammation strongly linked to HLA-A29. Doctors first rule out infections, then treat inflammation. PMC

2. Will I lose my vision?
   Many people keep useful vision with early, steady treatment and monitoring. Vision risk rises if macular edema or vasculitis is uncontrolled. National Eye Institute

3. Why do doctors suggest biologics like adalimumab?
   They reduce inflammation without long-term high-dose steroid toxicity and are FDA-approved for noninfectious uveitis. FDA Access Data

4. Are steroid eye implants safe?
   They can control inflammation for months to years, but raise cataract and eye-pressure risks. Regular checks are essential. FDA Access Data+1

5. Can I stop medicines when I feel better?
   Do not stop on your own. Tapering too fast can cause flares and more damage. National Eye Institute

6. Is there a diet that cures birdshot?
   No. A healthy Mediterranean-style diet supports general health but does not replace medical therapy. National Eye Institute

7. Does smoking really affect uveitis?
   Yes. Smoking is linked to higher uveitis risk and worse outcomes; e-cigarettes may also increase risk. Quitting helps. AAO Journal+1

8. How long will treatment last?
   Birdshot is chronic. Many patients need years of therapy with careful tapering and long-term follow-up. PMC

9. Are stem-cell injections helpful?
   No approved stem-cell treatments exist for birdshot uveitis; unregulated injections can blind. Consider only clinical trials. National Eye Institute

10. What tests track the disease?
    OCT for macular edema, fluorescein and indocyanine angiography for leakage and choroidal lesions, autofluorescence, and visual fields. PMC

11. Why check my blood before methotrexate or mycophenolate?
    These medicines can affect liver and blood counts; labs keep you safe while they protect your vision. FDA Access Data+1

12. Can I get pregnant while on these medicines?
    Some drugs (e.g., mycophenolate, methotrexate) are unsafe in pregnancy. Plan pregnancy with your uveitis and obstetric teams. FDA Access Data+1

13. Will I need cataract surgery?
    Maybe. Many patients develop cataracts over time due to disease and steroids. Surgery is successful when inflammation is quiet. Mount Sinai Health System

14. If one eye is worse, can I treat only that eye?
    Local therapy (injections/implants) can target one eye. Many patients also need systemic therapy to protect both eyes. FDA Access Data+1

15. What is the outlook with modern care?
    With early diagnosis, steroid-sparing strategies, and sustained follow-up, many patients maintain functional vision long-term. ophthalmologyretina.org

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 27, 2025.